$ cat ./records/biontech-expands-gates-foundation-mrna-partnership-to-malaria-hiv-2021.txt
BioNTech Expands Gates Foundation mRNA Partnership to Malaria, HIV, and Tuberculosis Programs
[RECORD.TXT] · cat --full
Following BioNTech's COVID-19 vaccine success with Pfizer, the company committed to advancing its pre-existing mRNA programs for HIV and tuberculosis — originally funded through the Gates Foundation's 2019 $55 million investment — and extended the platform to malaria vaccine development. BioNTech CEO Ugur Sahin publicly committed to deploying the company's mRNA expertise for diseases disproportionately affecting lower-income countries. The Gates Foundation's sustained partnership made BioNTech one of the central vehicles through which Gates pursued mRNA technology as a platform for global health.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Awards $1.28 Million to Oxitec to Develop Self-Limiting Cattle Tick Biocontrol
Next →
Gates Addresses Epstein Association in Multiple 2021 Interviews, Expresses Ongoing Regret
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.